Canine Dermal Safety Assessment for Global Cosmetics Brand
The Challenge
A Fortune 500 cosmetics manufacturer was preparing to launch a premium skincare line across the United States, European Union, and Japanese markets simultaneously. Their initial in vitro testing battery had produced ambiguous results for three key formulations containing novel active ingredients. Regulatory authorities in all three jurisdictions required definitive in vivo safety data before granting market authorization. The client faced a tight 12-month timeline to market and needed a testing partner capable of designing a comprehensive study protocol that would satisfy multiple regulatory frameworks simultaneously.
Our Solution
Our dermatology team designed a multi-phase GLP-compliant study protocol that addressed FDA 21 CFR Part 58, EU REACH Annex VIII requirements, and Japanese MHLW guidelines in a single integrated program. The study utilized our purpose-bred beagle colony with full veterinary oversight. Phase I covered acute dermal irritation assessment per OECD TG 404. Phase II addressed repeated-dose dermal toxicity over 90 days per OECD TG 410. Phase III included dermal sensitization evaluation per OECD TG 429. All phases incorporated histopathological analysis, clinical chemistry panels, and comprehensive clinical observations. Our animal welfare team implemented enrichment protocols exceeding USDA requirements throughout the study duration.
The Results
All 12 test formulations demonstrated safety margins exceeding regulatory thresholds by 3-5x across all endpoints. The integrated study design produced a single data package accepted by FDA, EMA, and PMDA without additional information requests. The client achieved simultaneous regulatory approval in all three target markets within 6 months of study completion. By consolidating what would traditionally require three separate study programs, Meramec saved the client an estimated $400,000 in redundant testing costs and 8 months of development timeline. The client has since engaged Meramec for two additional product line evaluations.